1587 related articles for article (PubMed ID: 15836747)
21. Omalizumab for treatment of allergic rhinitis.
Vashisht P; Casale T
Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
[TBL] [Abstract][Full Text] [Related]
22. Anti-IgE therapy of asthma.
Chung KF
Curr Opin Investig Drugs; 2002 Aug; 3(8):1157-60. PubMed ID: 12211407
[TBL] [Abstract][Full Text] [Related]
23. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
25. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
26. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
Owen CE
Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
[TBL] [Abstract][Full Text] [Related]
28. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
29. What is new in antiimmunoglobulin E asthma therapy.
Berger WE
Allergy Asthma Proc; 2005; 26(6):428-34. PubMed ID: 16541964
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab in asthma: approval and postapproval experience.
Chiang DT; Clark J; Casale TB
Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080
[TBL] [Abstract][Full Text] [Related]
31. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
[TBL] [Abstract][Full Text] [Related]
32. Omalizumab: a novel therapy for allergic asthma.
Davis LA
Ann Pharmacother; 2004; 38(7-8):1236-42. PubMed ID: 15187202
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
34. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
Hochhaus G; Brookman L; Fox H; Johnson C; Matthews J; Ren S; Deniz Y
Curr Med Res Opin; 2003; 19(6):491-8. PubMed ID: 14594521
[TBL] [Abstract][Full Text] [Related]
36. Omalizumab and the treatment of allergic rhinitis.
Kaliner MA
Curr Allergy Asthma Rep; 2004 May; 4(3):237-44. PubMed ID: 15056407
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
Hayden ML
J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
[TBL] [Abstract][Full Text] [Related]
39. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
Hamilton RG; Marcotte GV; Saini SS
J Immunol Methods; 2005 Aug; 303(1-2):81-91. PubMed ID: 16045925
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
